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Abstract 
Background:  Oxidative stress is a key feature of sepsis and could be a common pathophysiological pathway 
between septic shock and acute kidney injury (AKI) Our objective was to evaluate the erythrocyte superoxide dis‑
mutase (SOD1) activity as predictor of AKI in patients with septic shock.
Methods: This is a prospective observational study that evaluated 175 consecutive patients over the age of 18 years 
with septic shock upon intensive care unit (ICU) admission. However, 43 patients were excluded (27 due to AKI at 
ICU admission). Thus, 132 patients were enrolled in the study. At the time of the patients’ enrollment, demographic 
information was recorded. Blood samples were taken within the first 24 h of the patient’s admission to determine the 
erythrocyte SOD1 activity. All patients were followed throughout the ICU stay, and the development of AKI was evalu‑
ated. In addition, we also evaluated 17 control subjects.
Results: The mean age of patients with septic shock was 63.2 ± 15.7 years, 53 % were male and the median ICU stay 
was 8 days (4–16). Approximately 50.7 % developed AKI during the ICU stay. The median erythrocyte SOD1 activ‑
ity was 2.92 (2.19–3.92) U/mg Hb. When compared to control subjects, septic shock patients had a higher serum 
malondialdehyde concentration and lower erythrocyte SOD1 activity. In univariate analysis, erythrocyte SOD1 activity 
was lower in patients who developed AKI. The ROC curve analysis revealed that lower erythrocyte SOD1 activity was 
associated with AKI development (AUC 0.686; CI 95 % 0.595–0.777; p < 0.001) at the cutoff of <3.32 U/mg Hb. In the 
logistic regression models, SOD1 activity higher than 3.32 U/mg Hb was associated with protection of AKI develop‑
ment when adjusted by hemoglobin, phosphorus and APACHE II score (OR 0.309; CI 95 % 0.137–0.695; p = 0.005) and 
when adjusted by age, gender, chronic kidney disease, admission category (medical or surgery) and APACHE II score 
(OR 0.129; CI 95 % 0.033–0.508; p = 0.003).
Conclusions: In conclusion, our data suggest that erythrocyte SOD1 activity could play a role as an early marker of 
septic AKI and could be seen as a new research avenue in the field of biomarker in AKI. However, our study did not 
show a strong correlation between SOD activity and AKI. Nevertheless, these original data do warrant further research 
in order to confirm or not this hypothesis.
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Background
Acute kidney injury (AKI) is one of the most serious and 
frequent complications of sepsis in critically ill patients 
[1]. It is estimated that AKI develops within the first 24 h 
in 51–64 % of patients with sepsis with hypotension [2]. 
Septic shock is the major cause of death in the intensive 
care unit (ICU), and the presence of AKI in these patients 
leads to an increase in mortality [3].
The diagnosis of AKI is usually based on either an 
elevation of serum creatinine or the detection of oligu-
ria [4]. However, these tests have limited sensitivity and 
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specificity for the detection of renal dysfunction [5]. In 
this way, the development of biomarkers for the early 
detection of AKI is a research priority [6]. Some AKI 
markers are currently being intensely studied in several 
different clinical situations, mainly in critically ill patients 
[7–11]. However, some of these markers could be influ-
enced by systemic inflammation and infections, and early 
AKI predictors in patients with sepsis are still lacking.
A barrier to uncovering new specific biomarkers for 
sepsis-induced AKI is a lack of understanding of its 
pathophysiology. It is known that the oxidative stress 
caused by sepsis is one factor responsible for its devel-
opment [12, 13]. Oxidative stress is regulated by a bal-
ance between the rates of reactive oxygen species (ROS) 
generation and antioxidant systems, including superox-
ide dismutase (SOD), catalase, glutathione peroxidase, 
thioredoxin and vitamins [14]. SOD is considered to be 
the first line of defense against ROS because it catalyzes 
the dismutation of superoxide radicals to a less reactive 
product, hydrogen peroxide. Increased ROS production 
or an impaired antioxidant system will lead to oxidative 
damage to proteins, lipids and DNA. There is no ideal 
marker for oxidative stress; however, with regard to lipid 
peroxidation, malondialdehyde (MDA) is one of the most 
commonly used markers for the determination of oxida-
tive stress in humans [15].
Experimental and clinical studies of chronic kidney dis-
ease showed that SOD levels were reduced and markers 
of oxidative damage were increased in this scenario [16–
18]. In addition, strategies to increase SOD activity with 
recombinant SOD molecules and gene transfer led to 
reduced inflammation and oxidative stress in experimen-
tal models of ischemia–reperfusion and contrast-induced 
AKI [19–21]. It is also interesting to observe that in 
patients submitted to kidney transplantation, MDA levels 
were predictors of graft dysfunction [22, 23]. Despite the 
importance of oxidative stress, SOD1 activity has not yet 
been evaluated as predictor of AKI in patients with septic 
shock.
Therefore, the aim of our study was to evaluate the 
erythrocyte SOD1 activity as predictor of AKI in patients 
with septic shock.
Methods
This prospective observational study was conducted 
from May 2014 to June 2015 with patients admitted to 
the intensive care unit of our hospital. The protocol was 
approved by the ethics committee of our institution 
(30457414.7.0000.5411). Written informed consent was 
obtained from all patients or relatives prior to their inclu-
sion in the study.
This study was a subanalysis of a larger unpublished 
study, which evaluated the relationship between oxidative 
stress and mortality in patients with septic shock. The 
sample size was calculated using the Fisher and Belle 
formula, with the following variables: mortality rate of 
septic shock 40–60 %, 95 % confidence interval and 10 % 
sample error. The result was a minimum sample size of 
96 patients.
Patients were eligible for enrollment if they were 
18  years or older and had septic shock on ICU admis-
sion. Exclusion criteria were patients with AKI at ICU 
admission, patients with stage 4 or 5 chronic kidney 
disease (CKD) (creatinine clearance lower than 30  mL/
min/1.73  m2), a delay in septic shock diagnosis (longer 
than 24  h), pregnant women, patients with confirmed 
brain death, patients in palliative care, and those who 
used vasoactive drugs for <24 h.
At the time of the patients’ enrollment, demographic 
information, the Acute Physiology and Chronic Health 
Evaluation (APACHE II) score and the Sequential Organ 
Failure Assessment (SOFA) score were recorded. Blood 
samples were taken within the first 24 h of the patient’s 
admission, after hemodynamic stabilization, to deter-
mine the erythrocyte SOD1 activity. All patients were 
followed during their ICU stay, and the development of 
AKI was evaluated. Mortality rate and the length of the 
ICU stay were also recorded.
Septic shock was defined according to Survival Sepsis 
guidelines [24], and AKI was defined according to Kidney 
Disease Improving Global Outcomes (KDIGO) criteria, 
using the increase in serum creatinine ≥0.3 mg/dL within 
48 h or increase in serum creatinine ≥1.5 times baseline 
within 7  days [25]. Classification of AKI remains chal-
lenging because serum creatinine measurements, before 
the inciting illness, are often missing. In the absence of a 
standard method to accommodate missing values, inves-
tigators have used a variety of surrogate measures. One 
of these methods is to use the baseline creatinine as the 
lowest creatinine value in the last 6  months before AKI 
or, for those without this measurement, the lowest value 
achieved during hospitalization in the absence of dialysis 
[26, 27]. This was the definition we used of baseline cre-
atinine in our study. CKD was defined as glomerular fil-
tration rate lower than 60 mL/min/1.73 m2 using baseline 
creatinine and CKD Epidemiology Collaboration equation 
(CKD-EPI) (GFR =  141 ×  min(Scr/κ, 1)α ×  max(Scr/κ, 
1)  −  1.209  ×  0.993 Age  ×  1.018 [if female] _ 1.159 [if 
black], where Scr is serum creatinine, κ is 0.7 for females 
and 0.9 for males, α is −0.329 for females and −0.411 for 
males, min indicates the minimum of Scr/κ or 1, and max 
indicates the maximum of Scr/κ or 1) [28].
To understand the behavior of erythrocyte SOD1 activ-
ity in our patients with septic shock, we also evaluated 
these variables in 17 control subjects (non-hospitalized 
individuals without any acute disease).
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Laboratorial analysis
Total serum levels of sodium, potassium, phosphorus, 
C-reactive protein (CRP), albumin, creatinine and urea 
were measured using the dry chemistry method (Ortho-
Clinical Diagnostics VITROS 950®, Johnson & Johnson), 
and lactate was measured using a Roche OMNI® S Blood 
Gas Analyzer. Hemograms were performed with a Coulter 
STKS hematologic autoanalyzer (Luton/Bedfordshire, UK).
Serum MDA concentration
Serum MDA levels were analyzed based on the reac-
tion with thiobarbituric acid by high-performance liquid 
chromatography (HPLC) according to a method devel-
oped by Katepe [29]. UV detection was performed at 
532 nm.
Erythrocyte SOD1 activity
The SOD enzyme activity in erythrocytes was determined 
in a Lyasis biochemical analyzer according to methodol-
ogy recommended by the manufacturer (Ransod kit; Ran-
dox Laboratories Ltd., Crumlin, Antrim, UK) [30].
Statistical analysis
Data are expressed as the mean ± SD, the median (includ-
ing the lower and upper quartiles) or percentage. Com-
parisons between two groups for continuous variables 
were made using Student’s t test or the Mann–Whitney 
U test. Comparisons between two groups for categori-
cal variables were made using the χ2 test or Fisher’s exact 
test. Comparisons between continuous variables were 
made using Spearman correlation test. Receiver operat-
ing characteristic (ROC) curve analysis was performed to 
determine the performance of erythrocyte SOD1 activity 
to predict AKI development. A logistic regression model 
was used to predict AKI. We constructed two regression 
models. Erythrocyte SOD1 activity was tested as a cate-
gorical variable (>3.32 U/mg Hb, cutoff obtained by ROC 
curve). In the first model, erythrocyte SOD1 activity was 
adjusted with parameters that exhibited significant differ-
ences in the univariate analysis. The only exceptions were 
variables with high collinearity among them (urea, cre-
atinine, potassium, MDA, CKD and SOFA score). In the 
other, SOD1 was adjusted by age, gender, CKD, admis-
sion category (medical or surgery) and APACHE II score. 
Data analysis was performed using SigmaPlot software 
for Windows v12.0 (Systat Software Inc., San Jose, CA, 
USA). p values lower than 0.05 were considered statisti-
cally significant.
Results
During the study, 175 consecutive patients were admit-
ted with a diagnosis of septic shock in the ICU; how-
ever, 43 patients were excluded (presence of AKI at ICU 
admission: 27 patients; delay in septic shock diagnosis: 12 
patients; presence of advanced chronic kidney disease: 4 
patients). Thus, we evaluated 132 patients (Fig.  1). The 
mean age was 63.2 ± 15.7 years, 53 % were male and the 
median length of ICU stay was 8 days (4–16). The mor-
tality rate during the ICU stay was 65.9 %. Median eryth-
rocyte SOD1 activity was 2.92 (2.19–3.92) U/mg Hb.
Among those patients with septic shock, 50.7 % devel-
oped AKI during the ICU stay. We have baseline serum 
creatinine levels in 37 patients of 67 patients who devel-
oped AKI, and in 30 patients, we used the lowest value 
achieved during hospitalization in the absence of dialy-
sis. Regarding KDIGO stages, 17.9  % were classified as 
KDIGO 1, 19.4 % as KDIGO 2 and 62.7 % as KDIGO 3. 
The median time for AKI diagnosis based on KDIGO cri-
teria was 2.3 days after admission. Among patients who 
developed AKI, 24.5  % needed dialysis during the ICU 
stay. The APACHE II and SOFA scores were also higher 
in patients in the AKI group. The mortality rate increased 
more than 30 % in patients with AKI. There were no dif-
ferences between groups in the other demographic and 
clinical data (Table 1).
The laboratory data are presented in Table 2. Patients 
who developed AKI had higher levels of potassium, 
phosphorus, MDA, urea and creatinine and lower levels 
of hemoglobin at baseline than patients without renal 
injury.
Erythrocyte SOD1 activity was lower in patients who 
developed AKI [non-AKI: 3.62 (2.59–4.34) vs AKI: 2.62 
(2.02–3.63) U/mg Hb; p = 0.001; Fig. 2]. It is also impor-
tant to observe that, although creatinine levels at ICU 
admission were higher in patients who developed AKI 
during ICU stay, erythrocyte SOD1 activity was not cor-
related with serum creatinine at ICU admission (Fig. 3). 
Our patients with septic shock had higher levels of serum 
MDA concentration [septic shock (n:132): 1.43 (0.77–
2.19) µmol/L; controls (n:17): 0.86 (0.49–1.07) µmol/L; 
p =  0.003] and lower erythrocyte SOD1 activity [septic 
shock (n:132): 2.92 (2.19–3.92) U/mg Hb; controls (n:17): 
4.35 (3.32–4.68) U/mg Hb; p = 0.001] when compared to 
control subjects.
The ROC curve analysis revealed that lower erythro-
cyte SOD1 activity was associated with AKI development 
(AUC 0.686; CI 95 % 0.595–0.777; p < 0.001) at the cut-
off of <3.32 U/mg Hb [sensibility: 68.7 % (CI 95 % 57.6–
79.8 %); specificity: 55.4 % (CI 95 % 43.3–67.5 %); positive 
predictive value: 61.3 % (CI 95 % 50.3–72.3 %); negative 
predictive value: 63.2 % (CI 95 % 50.7–75.7 %)] (Table 3; 
Fig. 4).
In the logistic regression models, SOD1 activity 
higher than 3.32  U/mg Hb was associated with protec-
tion of AKI development when adjusted by hemoglobin, 
phosphorus and APACHE II score (OR 0.309; CI 95  % 
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0.137–0.695; p = 0.005) and when adjusted by age, gen-
der, CKD, admission category (medical or surgery) and 
APACHE II (OR 0.129; CI 95 % 0.033–0.508; p = 0.003; 
Table 4).
Discussion
The objective of our study was to evaluate the erythro-
cyte SOD1 activity as marker of AKI in patients with 
septic shock. Although our study is a preliminary data, 
it showed for the first time in septic shock patients that 
erythrocyte SOD1 activity plays a role as a biomarker of 
AKI.
Sepsis is defined as the presence (probable or docu-
mented) of infection together with a systemic inflam-
matory response [24]. Septic shock is defined as 
sepsis-induced hypotension that persists despite ade-
quate fluid resuscitation [24]. Regardless of the creation 
of international guidelines for the early diagnosis and 
treatment of septic shock, its mortality remains high. 
This mortality rate is even higher when septic shock is 
associated with AKI. In our study, the mortality rate 
increased more than 30 % in patients with AKI. Thus, the 
early detection and treatment of patients who develop 
AKI are extremely important.
Several studies were performed in different clinical 
settings to identify biomarkers for AKI prediction, most 
of them in critically ill patients [5–8, 10, 11]. Until now, 
there have been four major categories of biomarkers for 
AKI in these patients: functional markers, such as serum 
creatinine; up-regulated proteins, such as NGAL and 
IL-18; low molecular weight proteins, such as urine cys-
tatin C; and enzymes, such as alpha-glutathione s-trans-
ferase and pi-glutathione s-transferase [10]. Recently, the 
combination of urine tissue inhibitor of metalloprotein-
ase 2 and insulin-like growth factor binding protein 7, 
known as TIMP-2 × IGFBP7, was allowed for marketing 
by the US Food and Drug Administration [11]. Up-reg-
ulation of these markers in patients with AKI has been 
proposed to reflect their growth-inhibitory function due 
to G1 cell-cycle arrest, a known consequence of AKI [11]. 
Despite all of these new markers, the prediction of AKI in 
patients with septic shock is still challenging. A barrier to 
uncovering new biomarkers for this scenario is a lack of 
understanding of the pathophysiology of sepsis-induced 
AKI [12, 13]. However, oxidative stress is a key feature of 
sepsis and could be a common pathophysiological path-
way between septic shock and AKI [31].
Fig. 1 Flow diagram of studied patients with septic shock
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Oxidative stress is characterized as an imbalance 
between ROS and antioxidant pathways, leading to 
oxidative damage to proteins, lipids and DNA. At the 
Table 1 Demographic and  clinical data of  132 patients 
with septic shock
Data are expressed as the mean ± SD, median (including the lower and upper 
quartiles) or percentage
APACHE II Acute Physiology and Chronic Health Evaluation, SOFA Sequential 
Organ Failure Assessment, RBC red blood cells, CKD chronic kidney disease, MV 
mechanical ventilation, ICU intensive care unit
Variable Acute kidney injury p value
Yes (n = 67) No (n = 65)
Age (years) 67.0 (59.0–75.0) 64.0 (50.5–72.5) 0.20
Male, n (%) 35.0 (52.2) 35 (53.8) 0.99
APACHE II score 18.7 ± 6.0 16.0 ± 6.4 <0.001
SOFA score 10.0 (8.0–12.0) 8.0 (7.0–9.5) <0.001
RBC transfusions, n (%) 36 (53.7) 29 (44.6) 0.38
Steroids, n (%) 38 (56.7) 30 (46.2) 0.30
Admission category, n (%)
 Medical 18 (26.9) 27 (41.5) 0.11
 Surgery 49 (73.1) 38 (58.5)
Sepsis focus, n (%) 0.46
 Respiratory 42 (62.7) 34 (52.3)
 Abdominal 16 (23.8) 16 (24.6)
 Urinary 3 (4.5) 4 (6.2)
 Others 6 (9.0) 11 (16.9)
Dialysis, n (%) 11 (16.4) 0 (0) 0.002
CKD, n (%) 57 (85.1) 7 (10.8) <0.001
MV, n (%) 60 (89.6) 55 (84.6) 0.56
Length of ICU stay (days) 7.0 (5.0–15.0) 9.0 (4.0–16.5) 0.63
ICU mortality, n (%) 52.0 (77.6) 35.0 (53.8) 0.007
Table 2 Laboratory data of 132 patients with septic shock
Data are expressed as median (including the lower and upper quartiles)
CRP C-reactive protein
Variable Acute kidney injury p value
Yes (n = 67) No (n = 65)
Lactate (mmol/L) 2.2 (1.4–3.5) 2.1 (1.1–3.4) 0.78
Hemoglobin (g/dL) 11.0 (9.1–12.0) 11.6 (10.0–12.7) 0.025
Hematocrit (%) 32.0 ± 6.4 34.1 ± 5.7 0.06
Leukocytes (103/mm3) 16.6 (12.2–21.6) 16.3 (12.2–24.0) 0.89
Sodium (mmol/L) 145 (140–149) 141 (137–148) 0.21
Potassium (mmol/L) 4.5 ± 0.9 4.1 ± 0.7 0.013
Phosphorus (mg/dL) 4.7 (3.4–6.6) 3.9 (2.7–4.9) 0.004
Glycemia (mg/dL) 145 (118–186) 146 (115–184) 0.87
CRP (mg/dL) 36.0 (28.0–44.1) 32.0 (8.5–41.5) 0.07
MDA (µmol/L) 1.65 (1.02–2.52) 1.25 (0.60–2.01) 0.009
Albumin (g/dL) 2.3 (2.0–2.5) 2.1 (1.8–2.8) 0.61
Urea (mg/dL) 95 (67–159) 53 (32–86) <0.001




























Fig. 2 Erythrocyte SOD1 activity in patients with septic shock
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r: 0.02; p: 0.793
Fig. 3 Correlation of serum creatinine at ICU admission with erythro‑
cyte SOD1 activity
Table 3 Cross-tabulation of  erythrocyte SOD1 activity 
and acute kidney injury development
Erythrocyte SOD1 activity Acute kidney injury
Yes No Total
<3.32 U/mg Hb (positive) 46 29 75
≥3.32 U/mg Hb (negative) 21 36 57
Total 67 65 132
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nanomolar scale, ROS play an important role in physi-
ological processes by functioning as a second messenger 
in signal transduction pathways [32]. However, at the 
micromolar scale, ROS is associated with oxidative injury 
[32]. SOD is considered the first line of defense against 
ROS, consisting of three isoenzymes: copper/zinc SOD 
(SOD1), which is localized in the cytosol, nucleus and 
intermembrane space of mitochondria; manganese SOD 
(SOD2), which occurs in the mitochondrial matrix; and 
extracellular SOD (SOD3) [33]. SOD1 is the most abun-
dant member of the family of antioxidant enzymes, rep-
resenting approximately 90 % of SODs [34].
Experimental studies showed that SOD concentration 
and activity are reduced in chronic kidney injury [17, 
19–21]. Vaziri et al. showed that SOD concentration was 
reduced and nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase expression was increased in the 
kidneys of rats submitted to nephrectomy [17]. Addition-
ally, in studies with recombinant SOD molecules and 
SOD gene transfer, the animals submitted to these inter-
ventions presented reduced inflammation and oxidative 
stress in experimental models of ischemia–reperfusion 
and contrast-induced AKI [19–21].
In a clinical study with 134 individuals, Magalhães 
et al. compared hemodialyzed patients with healthy con-
trols and showed that the activity of SOD is reduced in 
patients with chronic renal failure undergoing hemodi-
alysis [16]. In our study, the activity of erythrocyte SOD1 
was also lower in patients who developed AKI. This 
association remains statistically significant, even after 
adjustments for confounding variables in multivariate 
regression analysis. It is also important to note that eryth-
rocyte SOD1 activity was lower and serum MDA concen-
tration was higher in septic shock patients compared to 
control subjects. Thus, our results suggest that patients 
with septic shock had an impaired SOD1 response and 
increased oxidative stress, and this behavior was more 
pronounced in patients who developed AKI. In addition, 
this lower SOD1 activity occurred in the first 24 h of ICU 
admission.
1 - Specificity











Cutoff < 3.32 U/mg Hb
AUC: 0.686; CI95%: 
0.595-0.777; p<0.001
Fig. 4 ROC curve for the association between erythrocyte SOD1 activity and AKI development
Table 4 Logistic regression model for  the prediction 
of acute kidney injury in 132 patients with septic shock
a Unadjusted
b Adjusted by gender, age, chronic kidney disease, admission category and 
APACHE II score
c Adjusted by APACHE II, phosphorus and hemoglobin
Variable OR IC 5–95 % p value
SOD1 >3.32 U/mg Hba 0.326 0.158–0.671 0.002
SOD1 >3.32 U/mg Hbb 0.129 0.033–0.508 0.003
SOD1 >3.32 U/mg Hbc 0.309 0.137–0.695 0.005
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The AUC of erythrocyte SOD1 activity was only 0.686; 
however, comparisons of AUCs of several biomarkers for 
AKI prediction showed also a poor performance with a 
huge variation in its values [35, 36]. Thus, our data sug-
gest that erythrocyte SOD1 activity could be used as an 
early predictive marker of AKI.
It is important to remember that patients with chronic 
kidney disease have an increased risk to develop AKI. 
This could explain why our patients who developed AKI 
had higher levels of creatinine at ICU admission. Despite 
that, there was no correlation between creatinine at ICU 
admission and erythrocyte SOD1 activity. Thus, our 
results were not influenced by the initial difference in 
kidney function.
Considering that the development of AKI in patients 
with sepsis is related to increased mortality, the identi-
fication of early biomarkers of renal injury is extremely 
important. Erythrocyte SOD1 activity was associ-
ated with AKI detection 2.3  days before the KDIGO 
criteria. Our results have important clinical implica-
tions because we were able to identify patients at risk 
of developing AKI earlier. Thus, patients at risk of AKI 
could be treated more aggressively, improving septic 
shock outcomes.
We should consider some limitations of this study. 
We only included patients from a single medical center. 
Regarding AKI definition, we only have baseline serum 
creatinine of 55 % of patients who developed AKI, for the 
others we used the lowest value achieved during hospi-
talization in the absence of dialysis. Moreover, AKI was 
defined based upon the serum creatinine levels and not 
urine output. In addition, due to the relatively small num-
ber of patients, analysis of SOD1 according to the stage 
of AKI was not performed. Timing of antibiotic dosing 
was also not recorded, and blood was taken within the 
first 24 h, which is a relatively large window. Finally, the 
AUC of erythrocyte SOD1 activity was only 0.686, and 
our study is a preliminary data with a limited internal and 
external validity. Despite these limitations, we strongly 
believe that our data contribute relevant knowledge 
regarding the roles of SOD as early predictor of AKI in 
patients with septic shock.
Conclusions
In conclusion, our data suggest that erythrocyte SOD1 
activity could play a role as an early marker of septic AKI 
and could be seen as a new research avenue in the field 
of biomarker in AKI. However, our study did not show a 
strong correlation between SOD activity and AKI. Never-
theless, these original data do warrant further research in 
order to confirm or not this hypothesis.
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